Experimentally, navitoclax kills cells inside a BAX/BAK-dependent method and brings about regression of lymphoid tumors in xenograft designs. It blocks a gene  called JAK2. By blocking JAK2 ruxolitinib slows down or stops the cancer cells developing and dividing. Navitoclax can be a specific drug. It really works by blocking proteins https://andresungzz.dailyblogzz.com/26616251/a-review-of-tirofiban-hydrochloride-monohydrate